Abbott India Ltd.
Snapshot View

17793.00 +280.80 ▲1.6%

23 July 2021, 04:00:00 P.M.
Volume: 714

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.abbott.co.in
Financial Indicators
Market Cap 37,843.52 Cr.
Earnings per share (EPS) 325.04 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 54.79 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 1,203.75 Trailing Twelve Months Ending 2021-03
Price to Book Value 14.79 Calculated using Price: 17,809.30
Dividend Yield 1.54 Period Ending 2021-03
No. of Shares Subscribed 2.12 Cr. 21,249,302 Shares
FaceValue 10
Company Profile

Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Abbott India Limited is a public limited company domiciled and incorporated in India under the provisions of the then Companies Act, 1913. The company is listed and traded on the Bombay Stock Exchange. It is traded on the National Stock Exchange under the ‘permitted category’.

Abbott India, a publicly listed company and a subsidiary of Abbott Laboratories, takes pride in offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.

One of India's fastest-growing pharmaceutical companies, Abbott India Limited is part of Abbott's global pharmaceutical business in India. It has expertise across product development, manufacturing, sales and customer service and dedicated to providing high-quality, reliable products with the expert clinical support customers need.

Abbott India provides quality healthcare through a mix of global and local products for people in India. Its in-house development and medical teams undertake product and clinical development tailored to the unique needs of the Indian market. Its employees work to produce high-quality, high-volume formulations using cost efficient processes. And, its trained personnel are dedicated to ensuring compliance with international quality standards.

Business area of the company

The company is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.

Products and Services offered by the company

  • Cardiovascular- Keeping heart healthy with breakthrough medical technologies.
  • Diabetes- Helping people with diabetes enjoy healthier, active lives.
  • Diagnostics- Bringing accurate, timely information to better manage health.
  • Neuromodulation- Innovative solutions to movement disorders and chronic pain treatment.
  • Nutrition- Nourishing body at every stage of life.
  • Pharmaceuticals- Helping people get and stay healthy with quality medicines.

Awards

  • 2013- Awarded Frost & Sullivan ‘MNC Pharmaceutical Company of the Year’ for the third consecutive year.
  • 2014 -Abbott, one of the largest diversified global healthcare companies and the number one pharmaceutical company in India, in partnership with the Indian Thyroid Society (ITS), announced the launch of a thyroid awareness initiative in Uttar Pradesh and Uttarakhand.            
  • 2014- Abbott was awarded the prestigious Golden Peacock Innovation Management Award at the 8th International Conference on Corporate Social Responsibility held in Bangalore. 
  • 2018- ‘Best Companies to Work’
  • 2018- Best Use Of Technology for Training Excellence in The Production of Learning Content
  • 2019- Company of the Year (Abbott India)
  • 2019- Brand of the Year (Thyronorm) by AWACS
  • 2019- Excellence in Content Development for e-detailing training - Rajni ka iPad by National Awards for Training and Development
  • 2019- Gold for Best Content in a B-2-B Marketing Campaign - Immersive storytelling (using AR) for doctors at the India Content Leadership Award
  • 2019- Outstanding patient support for Gutfit by CMO Asia
  • 2019- Gold Award for Best Use of Market Research - PR MomvsFlu by Global Customer Engagement.
  • 2020- Best Financial Content For The 75th Annual Report at India Content Leadership Awards
  • 2020- Cremaffin Plus - Brand Excellence Award in Pharmaceutical sector at ABP Brand Excellence Award.
  • 2020- GUTFIT - Best Patient Education Project Award at ZEE Business’s - National Healthcare Leadership Awards
  • 2020- UDILIV - Brand Of The Year -Bronz at the AWACS Award - Acute category
  • 2020- Best Patient-Centric Design At Pharmapack Europe - G’DoCon - Granule Dosing Concept of CREON SD 
  • 2020- Best Digital Media Content by a Healthcare Enterprise for Mother Against Influenza (MAI) at the India Content Leadership Awards

History and Milestones

Dr. Abbott’s spirit of entrepreneurship, innovation and caring lives on in culture, business and contributions to medical science. Read below for historical moments that highlights the pursuit of the extraordinary throughout the years.

  • 1888- Production of ‘alkaloidal’ medicine granules by Dr. Wallace C. Abbott, a 30-year-old practicing physician, begins in the rear of his People’s Drug Store in Chicago. Remedies contain the active ingredients of plants and herbs. First-year total sales reach $2,000.
  • 1894- Incorporated as the Abbott Alkaloidal Company. Abbott is a medical publisher as well as a manufacturer.
  • 1907- Expansion outside the United States for the first time with an office in London, England.
  • 1916- Production of first synthetic medicine, Chlorazene, a breakthrough antiseptic developed by British chemist Dr. Henry Dakin to treat wounded soldiers in World War I.
  • 1922- Development of Butyn by scientists Dr. Ernest Volwiler and Dr. Roger Adams, the first in a long line of breakthrough anesthetics to come from company.
  • 1929- Initial public offering provides shares for the first time in the year of the stock market crash that began the Great Depression. While the timing seems inauspicious, stock grows in value from that first day-and approximately 10,000 times over so far.
  • 1932- Expansion continues even at the height of the Great Depression thanks to leadership in new fields such as vitamins and intravenous solutions. “Few of the leading industrial organizations of the country,” notes Nation’s Commercemagazine, “can show a sounder record for the past year than the Abbott Laboratories.”
  • 1935- Introduction of Pentothal, which will be the world’s leading anesthetic for years to come and win inventors, Dr. Volwiler and Dr. Donalee Tabern, induction into the U.S. National Inventors Hall of Fame.
  • 1942- Abbott joins a consortium of pharmaceutical makers, at the behest of the U.S. Government, to ramp up production of penicillin for wartime use. Together it increase production more than 20,000%.
  • 1959- Adoption of Abbott “A” logo, a classic of industrial design that remains the cornerstone of visual identity to this day.
  • 1960- Reinvention in the 1960s under? President George? Cain is ?featured in the 2001 ?best-seller, Good to? Great- Why Some? Companies Make the ?Leap... and Others Don’t. Author Jim Collins? chose as one of 11 companies, out of 1,435, that had the product, service, organizational and people quality to engender truly great performance.
  • 1964- Acquisition of M&R Dietetics, with its popular baby formula, Similac, makes a leader in nutrition.
  • 1972- Introduction of the ABA-100 blood chemistry analyzer as well as Ausria, a breakthrough radioimmunoassay test for detecting serum hepatitis. This marks the beginning of modern diagnostics business, in which it quickly became a world leader.
  • 1985- Approval of the first licensed test to identify the HIV virus in blood, helping to secure the safety of the blood supply. This is one of greatest achievements and the first significant medical victory against what had, until then, seemed an unstoppable threat.
  • 1998- Introduction of Glucerna, a group of cereals, health shakes and snack bars formulated specifically for diabetics and others with dietary restrictions.
  • 2002- FDA approval of Humira, the first fully-human monoclonal antibody drug. It will go on to become the world's leading pharmaceutical product.
  • 2006- Launch of the Xience V drug-eluting stent. It goes on to become the market leader.
  • 2010- Continue its focus on globalism as it becomes the largest pharmaceutical company in India, the world’s second-largest country by population.
  • 2013- Beginning of a new era for Abbott, as a more global, consumer-focused company than ever before, it created a new, Fortune 200 corporation, AbbVie, from former proprietary pharmaceutical business.
  • 2014- Abbott establishes a strong new expression of its corporate identity with “Life. To The Fullest.” The company promotes its identity more vigorously than ever before, advertising to consumer audiences around the world and becoming the sponsor of the Abbott World Marathon Majors, a series of the world’s most prominent races.
  • 2014- With the launch of its cutting-edge continuous glucose monitoring system, FreeStyle Libre, Abbott revolutionizes diabetes care by eliminating the need for routine fingersticks.1
  • 2016- Abbott launches the first systems in its Alinity series, a family of diagnostics and informatics systems that represent a major leap forward in terms of reliability, cost, capacity, space efficiency, and ease of use. It are creating the future of diagnostic labs.
  • 2017- In its largest acquisition ever, Abbott acquires St. Jude Medical, adding breakthrough inventions and extensive expertise across the areas of cardiovascular and neuromodulation. Abbott now competes in nearly every area of cardiovascular health and holds the No. 1 or 2 positions in a variety of large, high-growth markets.
  • 2017- Abbott acquires Alere Inc., making Abbott the leader in point-of-care diagnostic technology filling out its array of diagnostics technologies. Abbott now holds the No. 1 position in rapid testing for cardiometabolic disease, infectious disease and in toxicology.
  • 2018- For women health, company has launched Estrabet Gel, Doxstem, Combinorm Wash, Fertifoid
  • 2019- To help improve diagnosis and treatment of thyroid disorders, bacterial vaginosis and Vitamin D, the company collaborated with Indian Thyroid Society (ITS) and Federation of Obstetric and Gynecological Societies of India (FOGSI) to initiate the Metabolic Women’s Health workshops.
  • 2020- Abbott has launched a new inactivated quadrivalent vaccine for influenza offering protection against four virus strains in India. It is the only 0.5 ml quadrivalent flu vaccine in India that has been approved for use in children below three years.
  • 2020- Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. 

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+1.60%
1 Week
+1.79%
1 Month
+8.39%
3 Month
+18.22%
6 Month
+23.44%
1 Year
+14.54%
2 Year
+106.25%
5 Year
+278.02%
9 years 2012-12 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 24.30 27.66 26.54 23.93 21.54 26.35 24.66 27.09 27.89
Return on Capital Employed (%) 36.11 41.07 39.98 37.55 33.96 40.61 37.88 36.54 37.52
Return on Assets (%) 11.41 14.22 11.20 13.39 15.12 18.01 16.90 18.36 18.78

Balance Sheet View Details

Particulars 9 years 2012-12 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 647 788 938 1,196 1,387 1,693 2,009 2,432 2,602
Non Curr. Liab. 31 443 432 29 35 41 62 210 190
Curr. Liab. 502 652 834 382 632 668 857 891 1,031
Minority Int.
Equity & Liab. 1,179 1,883 2,204 1,607 2,053 2,402 2,928 3,532 3,823
Non Curr. Assets 133 540 541 156 160 136 167 328 304
Curr. Assets 1,046 1,343 1,663 1,451 1,893 2,265 2,761 3,205 3,519
Misc. Exp. not W/O
Total Assets 1,179 1,883 2,204 1,607 2,053 2,402 2,928 3,532 3,823

Profit Loss View Details

Particulars 9 years 2012-12 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 1,653 2,276 2,289 2,615 2,903 3,299 3,679 4,093 4,310
Other Income 23 49 48 51 60 118 114 115 83
Total Income 1,675 2,325 2,338 2,666 2,963 3,417 3,793 4,208 4,393
Total Expenditure -1,451 -2,009 -1,978 -2,251 -2,508 -2,775 -3,075 -3,337 -3,391
PBIDT 224 317 360 415 455 641 718 871 1,002
Interest 0 0 -1 -3 -2 -4 -2 -9 -18
Depreciation -19 -22 -15 -14 -16 -16 -17 -60 -58
Taxation -70 -96 -115 -143 -160 -220 -249 -210 -235
Exceptional Items 10
PAT 145 198 229 255 277 401 450 593 691

Cash Flow View Details

Particulars 9 years 2012-12 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 101 155 215 249 307 153 499 626 727
Cash Fr. Inv. -59 -144 -187 -77 -155 -215 -257 -401 -72
Cash Fr. Finan. -42 -42 -58 -80 -90 -102 -143 -217 -582
Net Change 1 -31 -30 91 62 -165 99 8 73
Cash & Cash Eqvt 109 79 49 140 202 38 137 145 218

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99
Public 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01 25.01
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 13 Jul 2021
Shareholding for the Period Ended June 30 2021
Abbott India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Tue, 13 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0651
Name of the Signatory :- Krupa Anandpara
Designation :- Company Secretary and Compliance Officer
Tue, 13 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
In terms of Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations 2018 please find enclosed Certificate issued by KFin Technologies Private Limited Registrar and Share Agent of the Company for the first quarter ended June 30 2021.

Kindly acknowledge receipt of the same.

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone
Close Crossing Current Month High Close Crossing Current Month High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%